Johnson and Johnson: Impella ECP Pivotal Study Demonstrates Safety, Efficacy for Use in High-Risk PCI
October 29, 2024
October 29, 2024
NEW BRUNSWICK, New Jersey, Oct. 29 (TNSres) -- Johnson and Johnson issued the following news release:
DANVERS, Mass. - October 28, 2024 - Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported with Impella ECP, a novel transvalvular axial flow pump with compressible pump architecture. Impella ECP is a technology of Abiomed, part of Johnson & Johnson MedTech, and the global leader in h . . .
DANVERS, Mass. - October 28, 2024 - Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported with Impella ECP, a novel transvalvular axial flow pump with compressible pump architecture. Impella ECP is a technology of Abiomed, part of Johnson & Johnson MedTech, and the global leader in h . . .